Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis

Abstract

The aim of this study was to identify novel serological tumor markers for human prostate cancer (PCa). We compared the gene expression profile of PCa tissues to adjacent benign tissues of prostate using gene expression microarray. 1207 genes that were consistently different from adjacent benign tissues of prostate (paired t test, P<0.05) were selected as differentially expressed genes (DEGs). Among them, 652 DEGs were upregulated in PCa, whereas 555 DEGs were downregulated in PCa. In addition, two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) coupled with MS was performed to screen for candidate markers in the proteome of PCa and adjacent benign tissues of prostate. A total of 89 spots were significantly up-regulated (ratio≥2, P<0.01) in PCa samples, whereas 66 spots were down-regulated (ratio≤-2, P<0.01). Sixty gene products were identified among these spots. Moreover, 14 potential candidate markers, which were identified as differentially expressed molecules by both gene expression microarray and 2D-DIGE, were chosen for validation and analysis by ELISA. The serum levels of three proteins correlated well with the 2D-DIGE results. Furthermore, the increased serum level of Inosine monophosphate dehydrogenase II (IMPDH2) was significantly associated with the clinicopathological features of the patients with PCa, suggesting its potential as a serological tumor marker. These results demonstrated that integrative transcriptome and proteome analysis could be a powerful tool for marker discovery in PCa. We suggest IMPDH2 as a novel serological tumor marker for detection of early PCa and evaluation of tumor progression.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks

“…To identify statistically significant biochemical recurrence courses, recursive partitioning was performed on a single gene expression profile using the ‘party’ package from CRAN (Han et al, 2012) with accompanying biochemical recurrence data taken from (Glinsky et al, 2004, Taylor et al, 2010). Kaplan Meier plots of the risk of biochemical recurrence were produced using the ‘survival’ package and p-values from the log rank test were corrected using the Bonferroni correction method.…”

HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis

“…What's more, HnRNP-L can reportedly regulate the tumorigenic capacity of lung cancer [14, 15]. Furthermore, using two-dimensional electrophoresis and mass spectrometry, Zhao et al showed that HNRNP-L is differentially expressed in Pca [16]. However, the specific roles of HnRNP-L in Pca remain unclear.…”

Quantitative proteomic study of human prostate cancer cells with different metastatic potentials

“…Some studies of 2D-DIGE-based proteomics focused to identify novel clinically relevant proteins in PCa (24)(25)(26). In the present study, compared with normal prostate epithelial cells, eleven differentially expressed proteins were identified as potential candidates associated with prostate cancer metastases.…”